Ignite Creation Date:
2024-05-06 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 12:51 PM
Study NCT ID:
NCT03631706
Status:
COMPLETED
Last Update Posted:
2024-02-26
First Post:
2018-08-09
Brief Title:
M7824 Versus Pembrolizumab as a First-line 1L Treatment in Participants With Programmed Death-ligand 1 PD-L1 Expressing Advanced Non-small Cell Lung Cancer NSCLC
Sponsor:
EMD Serono Research Development Institute Inc
Organization:
EMD Serono
Organization Data
Organization:
EMD Serono
Class:
INDUSTRY
Study ID:
MS200647_0037
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
EMD Serono Research Development Institute Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck KGaA Darmstadt Germany | INDUSTRY |